Modified transferrin fusion proteins
AssigneeBiorexis Technology, Inc.
InventorChristopher P. Prior
Life of this patent
Estimating the term…
Abstract
The present invention discloses fusion proteins comprising transferrin, lactoferrin or melanotransferrin fused to glucagon-like peptide 1 (GLP-1). In one embodiment of the invention, the fusion protein displays increased serum half-life as compared to a GLP-1 peptide in an unfused state. The invention includes a pharmaceutical composition comprising the GLP-1 fusion protein of the invention and a carrier. The fusion protein of the invention can be administered to a subject for treatment of diseases or conditions treatable by GLP-1, including, but not limited to, diabetes, obesity, congestive heart failure and inflammatory bowel syndrome.
Claims47
A fusion protein comprising a transferrin (Tf) protein fused to a glucagon-like peptide-1 (GLP-1).
A modified Tf fusion protein comprising a Tf protein exhibiting reduced N-linked glycosylation fused at its N-terminus to a GLP-1 moiety comprising the sequence:
- His-Gly-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Val-Ser-Ser-Tyr-Leu-Glu-Gly-Gln-Ala-Ala-Lys-Glu-Phe-Ile-Ala-Trp-Leu-Val-Ala-Gly-Arg-Gly (SEQ ID NO:
- 67).
A fusion protein comprising a GLP-1 peptide fused at its C-terminus to the N-terminus of a Tf protein which exhibits reduced N-linked glycosylation as compared to a fully N-linked glycosylated Tf protein, wherein the serum half-life of the GLP-1 peptide is increased compared to the serum half-life of a GLP-1 peptide in an unfused state.
A fusion protein comprising lactoferrin or melanotransferrin protein fused to a glucagon-like peptide-1 (GLP-1).
Dependencies are inferred from the claim text.